Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$27,912,500
+$12,232,500 QoQ
Shares Held
550,000
+37.5% QoQ
Ownership
0.751%
of shares outstanding
% of Portfolio
4.47%
of 13F equity value
Holder Rank
#30
of 210 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Avidity Partners Management LP holds $524,784,316 across 27 Biotechnology names. ELVN ranks #5 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
2,104,184 | $205,115,856 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,398,948 | $99,395,255 | |
| 3 | ORKA |
Oruka Therapeutics, Inc.
|
760,424 | $72,369,552 | |
| 4 | JBIO |
Jade Biosciences, Inc.
|
1,700,708 | $37,789,731 | |
| 5 | ELVN |
Enliven Therapeutics, Inc.
This page
|
550,000 | $27,912,500 | |
| 6 | AKTS |
Aktis Oncology, Inc.
|
484,200 | $15,605,766 | |
| 7 | PVLA |
Palvella Therapeutics, Inc.
|
70,000 | $10,697,400 | |
| 8 | IMUX |
Immunic, Inc.
|
669,941 | $10,296,993 |
All Filings in ELVN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $27,912,500 | 550,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $15,680,000 | 400,000 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $2,160,620 | 140,300 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2,871,941 | 140,300 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $226,678 | 11,300 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $222,384 | 11,300 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||